Does reducing spasticity translate into functional benefit? An exploratory meta-analysis

H P Francis, D T Wade, L Turner-Stokes, R S Kingswell, C S Dott, E A Coxon

Background: Spasticity and loss of function in an affected arm are common after stroke. Although botulinum toxin is used to reduce spasticity, its functional benefits are less easily demonstrated. This paper reports an exploratory meta-analysis to investigate the relationship between reduced arm spasticity and improved arm function.

Method: Individual data from stroke patients in two randomised controlled trials of intra-muscular botulinum toxin were pooled. The Modified Ashworth Scale (elbow, wrist, fingers) was used to calculate a “Composite Spasticity Index”. Data from the arm section of the Barthel Activities of Daily Living Index (dressing, grooming, and feeding) and three subjective measures (putting arm through sleeve, cleaning palm, cutting fingernails) were summed to give a “Composite Functional Index”. Change scores and the time of maximum change were also calculated.

Results: Maximum changes in both composite measures occurred concurrently in 47 patients. In 26 patients the improvement in spasticity preceded the improvement in function with 18 showing the reverse. There was a definite relationship between the maximum change in spasticity and the maximum change in arm function, independent of treatment ($r = -0.2822, p = 0.0008, n = 137$). There was a clear relationship between the changes in spasticity and in arm function in patients treated with botulinum toxin (Dysport) at 500 or 1000 units ($p = -0.5679, p = 0.0090, n = 22; p = -0.4430, p = 0.0018, n = 477$), but not in those treated with placebo or 1500 units.

Conclusions: Using a targeted meta-analytic approach, it is possible to demonstrate that reducing spasticity in the arm is associated with a significant improvement in arm function.
were chosen on the basis that their designs were sufficiently similar to allow pooling of individual data. They were sponsored by the same company (Ipsen), used the same botulinum toxin (Dysport), and included directly comparable measures recorded at the same time intervals. The first trial was a dose-ranging study, comparing the effects of three different doses of botulinum toxin (500, 1000, 1500 units Dysport) against placebo. The second used a fixed dose (1000 units Dysport). All patients were assessed at baseline (week 0) and at weeks 4, 8, 12, and 16, which allowed the temporal relationship between changes in spasticity and function to be examined. All assessments were undertaken by investigators who were unaware of the patient’s treatment, and trained in the use of the measures assessed.

All patients had had a stroke at least 3 months prior to entry, and had significant spasticity in the affected arm (scoring greater than 2 of 4 on the MAS in at least two of three joints in the arm). Background information was collected on all patients on entry to the study and all patients gave informed consent. Patients who were receiving ongoing rehabilitation, primarily physiotherapy, continued with this treatment after botulinum toxin injection.

Data from the following measures were used in our analyses:

- The MAS for spasticity. As published this is scored 0–4, with a 1+ grade, but for data analysis the scores were adjusted to give a 0–5 score range (1+ became 2, 2 became 3, and so on). This scale was applied to the affected flexors at the elbow, wrist, and fingers. The scores were added, giving a “Composite Spasticity Index” from 0 to 15.

- The scores of the study subjective assessments (cleaning palm, cutting fingernails, and putting arm through sleeve) were added to those for three items from the Barthel Index, typically involving upper limb function (items 3, 5, and 8—grooming, feeding, and dressing) to form a “Composite Functional Index”.

Since the scales for the different assessments were scored in opposite directions, the subjective scores were adjusted for analysis, with low scores reflecting more severe impairment and high scores representing little impairment (see Appendix A). This gave a range for the “Composite Functional Index” of 0–17.

Two additional variables for each component (spasticity and function) were also calculated:

- A change score, comparing the index at each time point with the score at baseline.

- The peak time (assessment point), when the maximum change was first observed. If the peak occurred at only one point, that time was recorded, but if the peak response was observed at two or more points, the time at which it was first observed was recorded.

We investigated the timing of the maximum improvement in each index for each patient and the inter-relationship between the maximum change in spasticity index and the maximum change in functional index (that is, the relationship between the maximum change seen in each measure in each patient over the 16 weeks of observation). We also investigated the relationship between extent of change in spasticity and extent of change in arm function, regardless of the time of that change, using Spearman’s ranked correlation coefficient.

**RESULTS**

Full details of the patients are given in the original papers, but important relevant information is summarised in table 1. A total of 142 patients were recruited to the two studies and on entry data were available from 141. Some data were not available for every patient at every time point, accounting for the reduction to 137 patients in some analyses.

The timing of the maximum improvement in composite Spasticity Index and in Composite Functional Index in individual patients is shown in table 2. Ten patients showed no improvement at any time point. In addition, 31 showed a reduction in spasticity with no change in function, while only five showed an improvement in function without a change in spasticity. Where changes in both measures were observed, the time of maximum change coincided in 47 patients, usually (n = 34) at 4 weeks. Interestingly, 26 showed a maximum change in spasticity before a maximum change in arm function, while only 18 showed an improvement in arm function before reaching a maximum change in spasticity.

The relationship between the maximum change in spasticity and that in arm function in individual patients is shown in fig 1. Where available, data were included for each patient, independent of treatment. There was a clear association between improvement in spasticity and improvement in arm function (p = −0.2822, p = 0.0008, n = 137).

Examination of the separate treatment groups (fig 2) showed that in those patients treated with placebo, there was only a weak association between the maximal change in spasticity and the maximal change in arm function, which was not statistically significant (p = −0.2223, p = 0.1775, n = 49). The extent of the changes in these patients was smaller than in the individuals receiving the active treatment. In addition, 17 of these patients failed to show any improvement in spasticity and/or function.

In patients receiving botulinum toxin (Dysport) at 500 or 1000 units, the extent of the maximal changes in spasticity and in arm function were greater than in the placebo-treated group. There was a clear and statistically significant association.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Study 1</th>
<th>Study 2</th>
<th>Overall, baseline</th>
<th>Overall, week 4</th>
<th>Overall, week 16</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>83</td>
<td>59</td>
<td>142</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Placebo</td>
<td>19</td>
<td>32</td>
<td>51</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysport 500 units</td>
<td>22</td>
<td>22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysport 1000 units</td>
<td>22</td>
<td>27</td>
<td>49</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dysport 1500 units</td>
<td>19</td>
<td>19</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>77</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, mean (SD) years</td>
<td>64.0 (12.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subset of Barthel Index (items 3, 5, and 8), median (range)</td>
<td>3 (1–5)</td>
<td>3 (1–5)</td>
<td>3 (1–5)</td>
<td>3 (1–5)</td>
<td>3 (1–5)</td>
</tr>
<tr>
<td>Total Composite Spasticity Index, median (range)</td>
<td>11 (3–15)</td>
<td>11 (1–15)</td>
<td>11 (1–15)</td>
<td>8 (0–15)</td>
<td>9 (0–15)</td>
</tr>
<tr>
<td>Total Composite Functional Index, median (range)</td>
<td>7 (1–15)</td>
<td>7 (1–15)</td>
<td>7 (1–15)</td>
<td>8 (1–15)</td>
<td>8 (1–17)</td>
</tr>
</tbody>
</table>

**Table 1** Summary of data from patients studied
An exploratory meta-analysis

lack of a statistically significant correlation between these
neously or in response to therapy, following their stroke. The
expected since they may still have been improving, sponta-
number of patients.

change in spasticity and the change in function independent
undertaken without regard to the mechanism of spasticity

botulinum toxin reduces spasticity sufficiently to allow
improved function. They suggest that a moderate dose of
Detailed data from five time points collected in a standardised

This is the first study to investigate the relationship between
changes in spasticity and function, but this was not
statistically significant ($r = -0.1186, p = 0.6393, n = 19$). In
none of the patients was a deterioration in function observed
and in the majority (14/19) function clearly improved.

DISCUSSION

This is the first study to investigate the relationship between
changes in spasticity and changes in function in a large group
of patients, and has the particular advantage of having
detailed data from five time points collected in a standardised
manner. The results show that reducing spasticity can lead to
improved function. They suggest that a moderate dose of
botulinum toxin reduces spasticity sufficiently to allow
function to improve, without causing a substantial decrease
in strength, which may further impede function.

This analysis has several strengths. The main analysis was
undertaken without regard to the mechanism of spasticity
reduction and the results show a correlation between the
change in spasticity and the change in function independent
of treatment. Data collection was of a high quality in a large
number of patients.

In many patients treated with placebo, there were
improvements in both spasticity and function. This is to be
expected since they may still have been improving, sponta-
neously or in response to therapy, following their stroke. The
lack of a statistically significant correlation between these
changes may simply be due to the relatively high proportion
of patients who failed to show any change in spasticity and/or
function (n = 17). However, it is possible that the reduction in
spasticity seen after injecting saline (placebo) may be
qualitatively different, which might account for the reduced
strength of the relationship.

In patients treated with botulinum toxin, the changes in
both spasticity and function were consistently greater than in
those treated with placebo. The number of patients showing
no change in spasticity and/or function was higher among
those treated with placebo (23 of 49; 47%) than among those
receiving Dysport at any dose (27 of 88; 31%).

In the small number of patients treated with the highest
dose of botulinum toxin (Dysport 1500 units), there were
marked changes in spasticity. In this group, however, the
improvements in function tended not to be as large as in the
other groups and there was no significant correlation between
these measures. It is possible that this high dose
caused an over-weakening of the injected muscles, further
adding to the disability. Although it is also possible that the
lack of a statistically significant association is simply a
reflection of the low power relating to the smaller number of
patients receiving this treatment.

In addition to the association between changes in spasticity
and function, these analyses demonstrate a time lag between
these changes in many patients. This delay is unsurprising
because the patients are likely to need time to learn how to
use any reduced muscle tone. Indeed this study supports the
need for botulinum toxin use to be combined with active
rehabilitation (as it was with many of these patients) so that
they may capitalise on the window of opportunity offered by
any reduction in spasticity.

Among the data from these patients, however, there were
individuals in whom the maximal change in function
preceded the maximal change in spasticity. Where this
occurred it is presumed that benefit in function does not
require a maximal change in spasticity and may peak whilst
spasticity continues to improve.

An alternative explanation may lie in the relatively long
gaps (4 weeks) between the assessments. For example it is
possible that the peak changes may have occurred in both
parameters at 6 weeks after treatment, but were recorded at 4
and 8 weeks, since no measurements were made at 6 weeks.
This relatively infrequent assessment was one of the
limitations of this study, reducing the accuracy of the time
point of maximum change.

There were other limitations to this study. The measures
used were relatively crude, making it more difficult to
investigate the inter-relationship between spasticity and
function. Nonetheless, the data were much more extensive
than those in most other studies. A further criticism may be
that the summation of individual scores into a single
measure is not accepted in all circles as a valid technique,

Table 2  Timing of maximum improvement (first point) for spasticity and arm function, all
treatments

<table>
<thead>
<tr>
<th>Spasticity</th>
<th>Arm function</th>
<th>No improvement</th>
<th>Week 4</th>
<th>Week 8</th>
<th>Week 12</th>
<th>Week 16</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>No improvement</td>
<td>10</td>
<td>21</td>
<td>6</td>
<td>3</td>
<td>1</td>
<td>41</td>
<td></td>
</tr>
<tr>
<td>Week 4</td>
<td>3</td>
<td>34</td>
<td>5</td>
<td>6</td>
<td>2</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>Week 8</td>
<td>0</td>
<td>6</td>
<td>10</td>
<td>1</td>
<td>1</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>Week 12</td>
<td>1</td>
<td>3</td>
<td>5</td>
<td>1</td>
<td>3</td>
<td>13</td>
<td></td>
</tr>
<tr>
<td>Week 16</td>
<td>1</td>
<td>6</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>15</td>
<td>70</td>
<td>29</td>
<td>14</td>
<td>9</td>
<td>137</td>
<td></td>
</tr>
</tbody>
</table>

Underline, no improvement in one measure with improvement in the other; bold, concomitant maxima; below
diagonal, spasticity improved before function; above diagonal, function improved before maximum change in
spasticity.

Figure 1  The relationship between the maximal change in Composite Functional Index and the maximal change in Composite Spasticity Index in 137 stroke patients followed over 16 weeks. The numeral at each point indicates the number of patients exhibiting that change.
particularly where these include items from the different dimensions of functional ability. However, this approach has been quite widely applied in many areas of rehabilitation. Bakheit et al assessed spasticity on the whole arm by summing the MAS score at the different joints (elbow, wrist, and fingers) and Snow et al applied a summed score for the different dimensions of pain, deformity, and ease of care.

Another limitation in these studies was the inconsistent application of physiotherapy, which may have confounded some of the analyses. Throughout the course of the study, patients continued to receive their established regimen for this treatment. This varied from zero to 10 hours per week. There was a tendency for the patients receiving physiotherapy in addition to botulinum toxin, to gain greater benefit than those who received no physiotherapy and placebo treatment, but the large spread of these data precluded extensive analysis.

Previous studies may have failed to show functional benefit for several reasons. The amount of benefit is quantitatively (but not clinically) small and global measures of ADL will fail to detect it, as will small studies with inadequate power. Furthermore, in many patients, the timing of maximum change in spasticity occurs before the maximum change in function. If the primary outcome is only measured at one time point (as is traditionally required in randomised controlled trials) then the study risks missing at least one aspect of any benefit. Thirdly, many studies (especially those of oral drugs) do not include active rehabilitation and consequently patients may not realise the potential functional benefits of effective treatment.

From the patient’s point of view two points need emphasis. First, relieving spasticity may often be a goal in its own right, just as relieving pain is a sufficient goal for analgesic drugs. Spasticity is often uncomfortable, and sometimes very painful. Likewise simply making it easier to care for the spastic arm may be a valid, and even potentially cost-effective, goal. Second, moving from requiring “some help” to needing “no help” in dressing, for example, may only score one point on an ADL scale, but for the patient can make the difference between waiting for a carer in the morning and being able to get up at the time they choose.

The value of these small changes to the patients, despite a lack of statistical significance, was reflected in the single dose study, where 92% of patients reported a global benefit after botulinum toxin treatment, compared with 50% receiving placebo (p = 0.007, logistic regression and odds ratio). The investigators’ rating of the same item was 88% compared with 50%, respectively (p = 0.002, logistic regression and odds ratio).

We would recommend that future studies take a number of factors into account. They should have at least two primary outcome measures to reflect the different aspects of ill health, one at the level of impairment (spasticity) and one at the level of activities (function). These two primary outcome measures should be measured at a number of different time points, ideally on a number of occasions and at short intervals. Where possible, the functional measure should be restricted to those activities which might be expected to show benefit. Studies should also consider using goal attainment scaling or a similar approach (for example, global assessment of benefit) to acknowledge the various goals of treating focal spasticity. Finally, patients should have access to standardised regimens of rehabilitation (usually physiotherapy and/or occupational therapy) soon after starting treatment to enable them to take advantage of the reduced spasticity.
When these factors are taken into account, a clear link between reduced spasticity and increased function following botulinum toxin treatment is established.

ACKNOWLEDGEMENTS
We thank Professor Bakheit and all other investigators involved in the two published studies for all their work in collecting the original data.

CONTRIBUTIONS
The original idea came from HF, expanded later by DW and LT-S. All authors contributed to the development of the final paper. HF is the guarantor.

Authors’ affiliations
H P Francis, R S Kingswell, C S Dott, E A Coxon, Ipsen, 190 Bath Road, Slough, SL1 3XE, UK
D T Wade, Oxford Chair for Enablement, Windmill Road, Oxford, OX3 7LD, UK
L Turner-Stokes, Herbert Dunhill Chair of Rehabilitation, King’s College, London, UK

Competing interests: Ipsen produces and sells Dysport, a botulinum toxin type A and has an interest in showing treatment benefit. All authors have a financial relationship with Ipsen

APPENDIX A
Construction of the Composite Function Index is shown in table A1.

REFERENCES

<table>
<thead>
<tr>
<th>Table A1</th>
<th>Construction of the Composite Function Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjective assessments for each task (cleaning palms, cutting fingernails, putting arm through sleeve)</td>
<td>Items from Barthel ADL Index (arm section, items 3, 5, and 8)</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Cannot do this activity</td>
<td>4</td>
</tr>
<tr>
<td>A great deal of difficulty</td>
<td>3</td>
</tr>
<tr>
<td>Moderate difficulty</td>
<td>2</td>
</tr>
<tr>
<td>A little difficulty</td>
<td>1</td>
</tr>
<tr>
<td>No difficulty</td>
<td>0</td>
</tr>
</tbody>
</table>

www.jnnp.com
Does reducing spasticity translate into functional benefit? An exploratory meta-analysis

H P Francis, D T Wade, L Turner-Stokes, R S Kingswell, C S Dott and E A Coxon

J Neurol Neurosurg Psychiatry 2004 75: 1547-1551
doi: 10.1136/jnnp.2003.025551

Updated information and services can be found at:
http://jnnp.bmj.com/content/75/11/1547

These include:

References

This article cites 19 articles, 7 of which you can access for free at:
http://jnnp.bmj.com/content/75/11/1547#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Stroke (1449)
Drugs: CNS (not psychiatric) (1945)
Neuromuscular disease (1311)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/